A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept (MK-7962) Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension (PAH) on Standard of Care

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512278-92-00

Acronym

MK-7962-024

Enrollment

Registered

2024-11-25

Start date

2024-12-09

Completion date

2025-11-20

Last updated

2025-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Arterial Hypertension (PAH)

Brief summary

Steady-state average serum concentrations of sotatercept (Cavg), Number of participants who experience one or more adverse events (AEs), Number of participants who discontinue study intervention due to an AE

Detailed description

Initial dose average serum concentrations of sotatercept (Cavg)

Interventions

DRUGSOTATERCEPT

DRUGsotatercept

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Steady-state average serum concentrations of sotatercept (Cavg), Number of participants who experience one or more adverse events (AEs), Number of participants who discontinue study intervention due to an AE	—

Secondary

Measure	Time frame
Initial dose average serum concentrations of sotatercept (Cavg)	—

Countries

Czechia, France, Germany, Hungary, Italy, Netherlands, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026